{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:21:35Z","timestamp":1789150895089,"version":"build-2803163510"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s12185-020-03047-w","type":"journal-article","created":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T14:02:38Z","timestamp":1609596158000},"page":"600-605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9914-7517","authenticated-orcid":false,"given":"Takahiro","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumi","family":"Ubukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masumi","family":"Fujishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,2]]},"reference":[{"key":"3047_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.imbio.2008.11.014","volume":"214","author":"C Haas","year":"2009","unstructured":"Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterb\u00fcse R, Schlereth B, et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology. 2009;214:441\u201353.","journal-title":"Immunobiology"},{"key":"3047_CR2","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836\u201347.","journal-title":"N Engl J Med"},{"key":"3047_CR3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/jcph.1006","volume":"58","author":"M Zhu","year":"2018","unstructured":"Zhu M, Kratzer A, Johnson J, Holland C, Brandl C, Singh I, et al. Blinatumomab pharmacodynamics and exposure-response relationships in relapsed\/refractory acute lymphoblastic leukemia. J Clin Pharmacol. 2018;58:168\u201379.","journal-title":"J Clin Pharmacol"},{"key":"3047_CR4","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/leu.2017.41","volume":"31","author":"J Duell","year":"2017","unstructured":"Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A, et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. 2017;31:2181\u201390.","journal-title":"Leukemia"},{"key":"3047_CR5","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/ajh.24783","volume":"92","author":"I Aldoss","year":"2017","unstructured":"Aldoss I, Song J, Stiller T, Nguyen T, Palmer J, O\u2019Donnell M, et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia. Am J Hematol. 2017;92:858\u201365.","journal-title":"Am J Hematol"},{"key":"3047_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-015-0213-6","volume":"8","author":"T Kohnke","year":"2015","unstructured":"Kohnke T, Krupka C, Tischer J, Knosel T, Subklewe M. Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19\/CD3-bispecific T cell engager antibody blinatumomab. J Hematol Oncol. 2015;8:111.","journal-title":"J Hematol Oncol"},{"key":"3047_CR7","doi-asserted-by":"publisher","first-page":"76902","DOI":"10.18632\/oncotarget.12357","volume":"7","author":"J Feucht","year":"2016","unstructured":"Feucht J, Kayser S, Gorodezki D, Hamieh M, D\u00f6ring M, Blaeschke F, et al. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts. Oncotarget. 2016;7:76902\u201319.","journal-title":"Oncotarget"},{"issue":"Suppl 1","key":"3047_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1182\/blood-2018-99-111845","volume":"132","author":"J Webster","year":"2018","unstructured":"Webster J, Luskin MR, Prince GT, DeZern AE, DeAngelo DJ, Levis MJ, et al. Blinatumomab in combination with immune checkpoint inhibitors of PD-1 and CTLA-4 in adult patients with relapsed\/refractory (R\/R) CD19 positive B-Cell acute lymphoblastic leukemia (ALL): preliminary results of a Phase I study. Blood. 2018;132(Suppl 1):557.","journal-title":"Blood"},{"key":"3047_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-017-0074-5","volume":"6","author":"V Nagele","year":"2017","unstructured":"Nagele V, Kratzer A, Zugmaier G, Holland C, Hijazi Y, Topp MS, et al. Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed\/refractory ALL. Exp Hematol Oncol. 2017;6:14.","journal-title":"Exp Hematol Oncol"},{"key":"3047_CR10","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.3324\/haematol.2012.082248","volume":"98","author":"R Wong","year":"2013","unstructured":"Wong R, Pepper C, Brennan P, Nagorsen D, Man S, Fegan C. Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica. 2013;98:1930\u20138.","journal-title":"Haematologica"},{"key":"3047_CR11","doi-asserted-by":"publisher","first-page":"103958","DOI":"10.1016\/j.cellimm.2019.103958","volume":"344","author":"X Zhang","year":"2019","unstructured":"Zhang X, Zhang H, Chen L, Feng Z, Gao L, Li Q. TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia. Cell Immunol. 2019;344:103958.","journal-title":"Cell Immunol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03047-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-020-03047-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03047-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T18:27:21Z","timestamp":1616437641000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-020-03047-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,2]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["3047"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-03047-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,2]]},"assertion":[{"value":"26 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interests relative to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}